Merit Medical Systems Q3 2026 earnings

MMSI · 2026-10-29 16:07 AMC ET · 8-K on SEC · 10-Q on SEC

Merit delivered 9% organic constant currency revenue growth and raised full-year guidance.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$416.2M+8.4%-0.5%Ex. 99.1, income statement
EPS (GAAP)$0.70+50.0%+7.7%Ex. 99.1, income statement
EPS (adjusted)$1.12+21.7%+5.9%Ex. 99.1, income statement
Net income$42.3M+52.4%+9.6%Ex. 99.1, income statement
Adj. EBITDA$67.4M+22.7%+6.2%Ex. 99.1, income statement
Adj. EBITDA margin16.2%+1.5 pp+0.5 ppEx. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin 48.2% (52.8% non-GAAP)
  • Operating expenses $141.9M (+1.3% YoY)
  • One-offs in the quarter Contingent consideration benefit $0.04M; Corporate restructuring $0.03M; Acquisition-related $0.03M; Medical Device Regulation expenses $0.01M
  • Effective tax rate 24.2% (24.1% YoY)
  • Non-GAAP bridge Adds back amortization of intangibles, performance-based share-based compensation, corporate restructuring, acquisition-related expenses, and Medical Device Regulation expenses.

KPIs

MetricActualPrior quarterPrior yearChange
Cash and cash equivalents$503.6M$448.7M$446.4M+12.3%
Total debt obligations$747.5M$747.5M$747.5M0%
Available borrowing capacity$697M$697M$697M0%

Guidance

MetricGuidePrior guideChange
Total Revenue$1.635 - $1.642B$1.631 - $1.643BNarrowed
Non-GAAP Earnings Per Share$4.33 - $4.37$4.25 - $4.35Raised

What drove it

  • Revenue story Revenue grew 8.4% year-over-year, driven by 9% organic constant currency growth, excluding a strategic divestiture.
  • EPS story EPS growth was driven by higher revenue and improved non-GAAP operating margins.
  • One-off check Contingent consideration benefit of $0.04M (pre-tax) in Q3 2026.

The good

  • 9% organic constant currency revenue growth
  • Non-GAAP operating margin increased 17% YoY
  • Non-GAAP EPS increased 22% YoY

The bad

  • GAAP gross margin decreased 0.3 pp YoY to 48.2%
  • Revenue declined 0.5% sequentially

The ugly

  • none

Open questions

  • The release does not disclose revenue by segment or region.
  • The release does not provide a reconciliation of GAAP to non-GAAP measures.
Full release

Earnings: MMSI — filed 2026-10-29

Merit Medical Systems Inc (MMSI) · Form 8-K, Item 2.02 · Filed · SEC filing

​

​

FOR IMMEDIATE RELEASE

MERIT MEDICAL REPORTS THIRD QUARTER 2026 RESULTS: DELIVERS 9% ORGANIC CONSTANT CURRENCY REVENUE GROWTH AND RAISES FULL-YEAR 2026 GUIDANCE

Financial Highlights†

† Comparisons above are calculated for the current quarter compared with the third quarter of 2025, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts.

* Constant currency revenue; constant currency revenue, organic; non-GAAP gross profit and margin; non-GAAP operating income and margin; non-GAAP net income; non-GAAP EPS; and free cash flow figures (used here and below) are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading “Non-GAAP Financial Measures” below.

SOUTH JORDAN, Utah, October 29, 2026 -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced financial results for the three and nine-month periods ended September 30, 2026.

“Merit delivered third quarter financial results that exceeded the high end of our expectations, driven primarily by 9% organic, constant currency revenue growth, excluding the impact of a strategic divestiture,” said Martha G. Aronson, Merit’s President and CEO. “We experienced strong revenue growth trends in the U.S. and better-than-expected demand for Merit’s products across both our Foundational and our Therapeutic platforms. We also delivered strong growth in both our non-GAAP operating profit and our non-GAAP earnings per share, which increased 17% and 22%, respectively, year-over-year.” Ms. Aronson¹ continued: “We have raised our 2026 revenue and non-GAAP earnings per share guidance to reflect the stronger-than-expected results over the first nine months of 2026 and remain confident in our team’s ability to execute, with attractive constant currency growth, improving profitability, and solid cash flow generation this year. Our team remains focused on delivering our Continued Growth Initiative financial targets for the three-year period ending December 31, 2026, and, in parallel, we are finalizing our longer-term strategic plan focused on identifying opportunities to better position the company for sustainable growth, enhanced profitability and value creation for our shareholders.”

Merit’s revenue by product category for the three and nine-month periods ended September 30, 2026 and 2025 was as follows (unaudited; in thousands, except for percentages):

​²

Financial Summary:

GAAP gross margin was 48.2%, compared to 48.5% for the third quarter of 2025. Non-GAAP gross margin* was 52.8%, compared to 53.6% for the third quarter of 2025.

GAAP operating margin was 14.1%, compared to 11.1% for the third quarter of 2025. Non-GAAP operating margin* was 21.3%, compared to 19.7% for the third quarter of 2025.

GAAP net income was $42.3 million, or $0.70 per share, compared to $27.8 million, or $0.46 per share, for the third quarter of 2025. Non-GAAP net income* was $67.4 million, or $1.12 per share, compared to $54.9 million, or $0.92 per share, for the third quarter of 2025.

As of September 30, 2026, Merit had cash and cash equivalents of $503.6 million and total debt obligations of $747.5 million, compared to cash and cash equivalents of $446.4 million and total debt obligations of $747.5 million as of December 31, 2025. Merit had available borrowing capacity of approximately $697 million as of September 30, 2026.

Fiscal Year 2026 Financial Guidance

Based upon the information currently available to Merit’s management, for the twelve-month period ending December 31, 2026, absent the potential impact of trade policies and related actions implemented by the U.S. and other countries subsequent to today’s date, material acquisitions, non-recurring transactions or other factors beyond Merit’s current expectations, Merit anticipates the following financial results:

​

Revenue and Earnings Guidance*

​

*Percentage figures approximated; dollar figures may not foot due to rounding.

Financial statements

Income Statement

Revenue and Earnings Guidance*

Updated Guidance – Year Ending – December 31, 2026Updated Guidance – % Change – Y/YPrior Guidance(2) – Year Ending – December 31, 2026Prior Guidance(2) – % Change – Y/Y
Total Revenue$1.635 - $1.642 billion8% - 8%$1.631 - $1.643 billion8% - 8%
Non-GAAP Earnings Per Share(1)$4.33 - $4.3713% - 14%$4.25 - $4.3511% - 14%

Income Statement

Three Months Ended — (Unaudited, in thousands except per share amounts)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
Net sales416,244384,1571,216,9641,121,970
Cost of sales215,613197,746616,370579,052
Gross profit200,631186,411600,594542,918
Operating expenses:
Selling, general and administrative119,511119,801366,950340,384
Research and development22,39323,96670,39170,811
Contingent consideration (benefit) expense-3632-701,198
Total operating expenses141,868143,799437,271412,393
Income from operations58,76342,612163,323130,525
Other income (expense):
Interest income4,1283,61511,78011,166
Interest expense-7,333-6,754-25,977-20,097
Other income (expense) — net227-93311,519-1,717
Total other expense — net-2,978-4,072-2,678-10,648
Income before income taxes55,78538,540160,645119,877
Income tax expense13,47410,78538,53629,394
Net income42,31127,755122,10990,483
Earnings per common share
Basic0.710.472.051.53
Diluted0.70.462.031.49
Weighted average shares outstanding
Basic59,80659,24559,66659,095
Diluted60,37959,91960,13460,604

Income Statement

Three Months Ended — (Unaudited, in thousands except per share amounts)

Three Months Ended – September 30, 2026 – Pre-TaxThree Months Ended – September 30, 2026 – Tax ImpactThree Months Ended – September 30, 2026 – After-TaxThree Months Ended – September 30, 2026 – Per Share Impact
GAAP net income55,785-13,47442,3110.7
Cost of Sales
Amortization of intangibles18,996-4,48414,5120.24
Operating Expenses
Contingent consideration benefit-36-14-500
Amortization of intangibles2,540-6001,9400.03
Performance-based share-based compensation (a)7,173-6656,5080.11
Corporate restructuring (b)301-712300
Acquisition-related280-112690
Medical Device Regulation expenses (c)519-1233960.01
Other (Income) Expense
Long-term debt costs (e)1,414-3341,0800.02
Other non-operating loss (f)254-601940
Non-GAAP net income87,226-19,83667,3901.12
Diluted shares60,379

Income Statement

Three Months Ended — (Unaudited, in thousands except per share amounts)

Three Months Ended – September 30, 2025 – Pre-TaxThree Months Ended – September 30, 2025 – Tax ImpactThree Months Ended – September 30, 2025 – After-TaxThree Months Ended – September 30, 2025 – Per Share Impact
GAAP net income38,540-10,78527,7550.46
Cost of Sales
Amortization of intangibles19,212-4,53914,6730.24
Inventory mark-up related to acquisitions183-431400
Operating Expenses
Contingent consideration expense32-5270
Amortization of intangibles2,560-6041,9560.03
Performance-based share-based compensation (a)9,028-1,4137,6150.13
Corporate restructuring (b)286-672190
Acquisition-related-6816-520
Medical Device Regulation expenses (c)1,655-3911,2640.02
Other (d)74-17570
Other (Income) Expense
Long-term debt costs (e)1,414-3341,0800.02
Other non-operating loss (f)260-611990
Non-GAAP net income73,176-18,24354,9330.92
Diluted shares59,919

Income Statement

Nine Months Ended — (Unaudited, in thousands except per share amounts)

Nine Months Ended – September 30, 2026 – Pre-TaxNine Months Ended – September 30, 2026 – Tax ImpactNine Months Ended – September 30, 2026 – After-TaxNine Months Ended – September 30, 2026 – Per Share Impact
GAAP net income160,645-38,536122,1092.03
Cost of Sales
Amortization of intangibles55,941-13,20642,7350.71
Operating Expenses
Contingent consideration benefit-70-9-790
Amortization of intangibles7,490-1,7685,7220.1
Performance-based share-based compensation (a)19,602-1,72717,8750.3
Corporate restructuring (b)2,460-5811,8790.03
Acquisition-related7,091-9166,1750.1
Medical Device Regulation expenses (c)2,589-6111,9780.03
Other (Income) Expense
Long-term debt costs (e)9,305-2,1977,1080.12
Gain on disposal of business unit-12,5021,520-10,982-0.18
Other non-operating loss (f)1,079-2678120.01

Income Statement

Nine Months Ended — (Unaudited, in thousands except per share amounts)

Nine Months Ended – September 30, 2025 – Pre-TaxNine Months Ended – September 30, 2025 – Tax ImpactNine Months Ended – September 30, 2025 – After-TaxNine Months Ended – September 30, 2025 – Per Share Impact
GAAP net income119,877-29,39490,4831.49
Cost of Sales
Amortization of intangibles55,798-13,18442,6140.7
Inventory mark-up related to acquisitions250-591910
Operating Expenses
Contingent consideration expense1,198291,2270.02
Amortization of intangibles7,497-1,7715,7260.09
Performance-based share-based compensation (a)19,681-2,34417,3370.29
Corporate restructuring (b)2,873-6782,1950.04
Acquisition-related2,088-22,0860.03
Medical Device Regulation expenses (c)4,883-1,1533,7300.06
Other (d)103-24790
Other (Income) Expense
Long-term debt costs (e)4,242-1,0023,2400.05
Other non-operating loss (f)11-61-500
Non-GAAP net income218,501-49,643168,8582.79
Diluted shares60,604

Income Statement

Three Months Ended — (Unaudited, in thousands except percentages)

Three Months Ended – September 30, 2026 – AmountsThree Months Ended – September 30, 2026 – % SalesThree Months Ended – September 30, 2025 – AmountsThree Months Ended – September 30, 2025 – % SalesNine Months Ended – September 30, 2026 – AmountsNine Months Ended – September 30, 2026 – % SalesNine Months Ended – September 30, 2025 – AmountsNine Months Ended – September 30, 2025 – % Sales
Net Sales as Reported416,244384,1571,216,9641,121,970
GAAP Operating Income58,76314.1%42,61211.1%163,32313.4%130,52511.6%
Cost of Sales
Amortization of intangibles18,9964.6%19,2125.0%55,9414.6%55,7985.0%
Inventory mark-up related to acquisitions1830.0%2500.0%
Operating Expenses
Contingent consideration (benefit) expense-36-0.0%320.0%-70-0.0%1,1980.1%
Amortization of intangibles2,5400.6%2,5600.7%7,4900.6%7,4970.7%
Performance-based share-based compensation (a)7,1731.7%9,0282.4%19,6021.6%19,6811.8%
Corporate restructuring (b)3010.1%2860.1%2,4600.2%2,8730.3%
Acquisition-related2800.1%-68-0.0%7,0910.6%2,0880.2%
Medical Device Regulation expenses (c)5190.1%1,6550.4%2,5890.2%4,8830.4%
Other (d)740.0%1030.0%
Non-GAAP Operating Income88,53621.3%75,57419.7%258,42621.2%224,89620.0%

Balance Sheet

September 30, — (in thousands)

September 30, – 2026December 31, – 2025
fp
ASSETS(Unaudited)
Current Assets
Cash and cash equivalents503,551446,404
Trade receivables, net221,866203,710
Other receivables37,87517,773
Inventories391,022333,705
Prepaid expenses and other current assets35,18831,493
Prepaid income taxes5,0304,941
Income tax refund receivables4,2832,128
Total current assets1,198,8151,040,154
Property and equipment, net437,347428,401
Intangible assets, net591,204537,654
Goodwill537,135506,837
Deferred income tax assets7,2737,049
Right-of-use operating lease assets84,37987,600
Other assets68,75378,227
Total Assets2,924,9062,685,922
Current Liabilities
Trade payables66,28660,551
Accrued expenses174,024159,486
Short-term operating lease liabilities10,38210,876
Income taxes payable14,3918,851
Total current liabilities265,083239,764
Long-term debt737,404734,038
Deferred income tax liabilities37,21619,665
Liabilities related to unrecognized tax benefits2,2482,248
Deferred compensation payable19,37317,542
Deferred credits1,3211,398
Long-term operating lease liabilities74,27376,658
Other long-term obligations43,43710,306
Total liabilities1,180,3551,101,619
Stockholders' Equity
Common stock808,930763,909
Retained earnings946,139824,030
Accumulated other comprehensive loss-10,518-3,636
Total stockholders' equity1,744,5511,584,303
Total Liabilities and Stockholders' Equity2,924,9062,685,922

Cash Flow

Nine Months Ended — (Unaudited, in thousands)

Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income122,10990,483
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization93,38391,629
Gain on disposition of a business-12,557-249

(1) Merit’s non-GAAP earnings per share reflect the dilutive impact of its 3.00% Convertible Senior Notes due 2029 (the “Convertible Notes”) calculated using the if-converted method of approximately $0.01 per share for the year ending December 31, 2026. Any offsetting impacts of the capped call associated with the Convertible Notes are not considered.

(2) “Prior Guidance” reflects Merit’s full-year 2026 financial guidance, previously introduced on July 30, 2026.

Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of various items which could impact Merit’s future financial results, such as expenses attributable to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reasonably predict the amount and impact of these items and Merit believes inclusion of the most comparable GAAP financial measure, and a reconciliation of these forward-looking non-GAAP measures to their GAAP counterparts could be confusing to investors or cause undue reliance.

Merit’s financial guidance for the year ending December 31, 2026 is subject to risks and uncertainties identified in this release and Merit’s filings with the SEC. This guidance is based on information and estimates available to Merit as of October 29, 2026. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results will likely vary, and could vary materially, from past results and those anticipated, estimated or projected.³

​

CONFERENCE CALL

As previously announced, Merit will hold its investor conference call today, Thursday, October 29, 2026, at 4:30 p.m., Eastern Time, to discuss its results for the third quarter and provide an operational update.

To access the conference call, please pre-register using the following link.

Registrants will receive confirmation with dial-in details.

A live webcast and slide deck will also be available at merit.com.

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.